Skip to main content

Table 3 Patient’s genomic landscape by circulating tumor DNA (ctDNA) sequencing

From: Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

Pt ID

Tumor Histology

DCB

TMB (mut/Mb)

NbVarCalls

Variant (gene; point mutation; variant allelic frequency; coverage)

01

Colorectal carcinoma

No DCB

10,9

13

PIK3CA; p.Glu545Lys; 4%; 900X

AKT1; p.Glu17Lys; 4%; 992X

GNAS; p.Arg201His; 4%; 299X

02

Renal cell carcinoma

No DCB

2,52

3

NA

03

Cervical cancer

DCB

2,52

3

DNMT3A; p.Phe521SerfsTer24; 25%; 1023X

04

Gastric cancer

No DCB

0,84

1

NA

05

Undifferentiated carcinoma of nasopharyngeal type

DCB

2,51

3

NA

06

Cervical cancer

DCB

0,84

1

NA

07

Mesothelioma

No DCB

5,05

6

PTEN; p.Tyr65Ter; 7%; 408X

NOTCH1; p.[Gln2393His;Gln2394Ter]; 16%; 309X

08

Neuroendocrine tumor

No DCB

3,35

4

KRAS; p.Gly12Asp; 25%; 449X

TP53; p.Glu343Ter; 53%; 1533X

09

Triple Negative Breast Cancer

No DCB

3,35

4

TP53; p.Trp91Ter; 23%; 714X

11

Thymic carcinoma

DCB

4,19

5

NA

12

Thymic carcinoma

DCB

5,03

6

CDKN2A; p.Val59AlafsTer79; 88%; 1212X

TP53; p.Arg282Pro;66%; 1895X

13

Mesothelioma

No DCB

3,32

4

NA